Read the latest press releases for 4D pharma plc.

Click on a news title to read full details. For Regulatory News Service (RNS) announcements please click here.

Press release archive
Clinical
Preliminary safety and clinical observations from its Phase I/II study of MRx0518 in combination with KEYTRUDA®
6 Nov 2019, 08:00
4D pharma plc (AIM: DDDD), a clinical-stage pharmaceutical company leading the development of Live…
Publications
4D pharma collaborates with MSD to develop Live Biotherapeutics for vaccines
8 Oct 2019, 07:00
4D pharma plc today announces that the Company has entered into a research collaboration and option…
Publications
Publication of data on neurodegenerative disease programmes
23 Sep 2019, 09:00
4D pharma announces the publication of data highlighting the neuroprotective properties of MRx0005…
Appointment of independent Non-Executive Director
27 Aug 2019, 09:00
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics,…
Oncology Programmes Update
25 Jul 2019, 09:00
Second-generation Live Biotherapeutic Identified and Mechanistic Data on MRx0518 and MRx1299…
4D pharma plc commences Phase I/II asthma trial
8 Jul 2019, 09:00
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics,…
4D to present Phase Ib results of Thetanix in paediatric Crohn's disease at ESPGHAN meeting
6 Jun 2019, 10:00
4D pharma plc (AIM: DDDD) today announced that data from the completed Phase Ib clinical study of…
4D presents MRx0518 combination study at ASCO 2019, Chicago, USA
3 Jun 2019, 09:00
4D pharma plc announces the presentation of a poster detailing its Phase I/II clinical study of…
4D to Present Phase Ib Clinical Data on Thetanix®
16 May 2019, 09:00
4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of Live…
4D announces participation in Neuro4D Conference, Frankfurt, Germany
13 May 2019, 08:00
4D’s Research and Development team is giving a poster presentation on preclinical data from the…
4D to present preclinical data on neurodegenerative disorders programme
2 May 2019, 09:00
4D pharma will present preclinical data on its neurodegenerative disorders programme targeting…
Clinical Update – MRx0518 oncology programmes
29 Apr 2019, 09:00
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics,…
Participation in Microbiome Conference
8 Mar 2019, 09:00
4D announces participation in Chardan’s Inaugural Microbiome Medicines Summit, USA
4D pharma publishes mechanistic data on MRx0518
29 Jan 2019, 09:00
4D pharma announces publication of data highlighting immuno-stimulatory properties of MRx0518
4D pharma Appoints Two Non-Executive Directors
8 Jan 2019, 09:00
4D pharma plc announces the appointment of Ed Baracchini, PhD, and Professor Axel Glasmacher, MD, as…

BACK TO TOP